Raise closed, search for fresh raises on Seedstage

Gaithersburg, MD

Developing AI-powered blood tests for early cancer detection and chronic disease prevention.

• AI-Powered Diagnostics: 20/20 Biolabs uses AI to enhance the accuracy and accessibility of its blood tests.
• Multi-Cancer Early Detection: The company is a leader in the MCED market, offering tests that detect multiple cancers from a single blood sample.
• Longevity Test Launch: A new test integrating biomarkers and dietary data is set to launch, providing personalized health recommendations.
• Retail Expansion: Partnerships with retail chains like Giant Food aim to make blood tests more accessible to the public.
• Strong IP Portfolio: The company holds multiple patents in the U.S. and East Asia, supporting its innovative diagnostic solutions.

20/20 Biolabs is developing and commercializing AI-powered blood tests for the early detection and prevention of cancers and chronic diseases. The company is expanding its product offerings to include a new longevity blood test, which integrates inflammatory biomarkers and dietary data to provide personalized lifestyle recommendations. This expansion aims to make early detection accessible, affordable, and accurate for a broader audience.

The company is leveraging its expertise in AI and diagnostics to enhance its current offerings and introduce new tests. With a strong intellectual property portfolio and partnerships with major diagnostic companies like Abbott and Roche, 20/20 Biolabs is positioned to grow in the Multi-Cancer Early Detection (MCED) market. The company is also exploring retail expansion opportunities to increase accessibility to its tests.

Company Info

20/20 Biolabs develops AI-powered blood tests for early cancer detection and chronic disease prevention.

20/20 Biolabs specializes in developing and commercializing AI-powered blood tests for the early detection and prevention of cancers and chronic diseases. Their flagship product, OneTest, is a multi-cancer early detection (MCED) test that identifies multiple cancers from a single blood sample, aiming to make early detection accessible, affordable, and accurate. The company leverages technology from Abbott and Roche Diagnostics and has a strong intellectual property portfolio with multiple patents.

In addition to cancer detection, 20/20 Biolabs is expanding into preventive health with their upcoming OneTest for Longevity, which focuses on chronic inflammation management. This test integrates inflammatory biomarkers, dietary data, and AI to provide personalized health recommendations. The company operates a CLIA-licensed, CAP-accredited laboratory and collaborates with various partners to enhance their offerings and expand their market reach.